Thymosin ␤4: potential to treat epidermolysis bullosa and other severe dermal injuries Thymosin ␤4 is a naturally-occurring regenerative protein present in almost all cells and body fluids, including wound fluid. In multiple preclinical injury models, it promotes dermal repair and tissue regeneration. Thymosin ␤4 acts by increasing keratinocyte/epithelial cell migration, angiogenesis, and cell survival, and by decreasing inflammation, apoptosis, and scarring. It also modulates cytokines, including those that cause itching. Thymosin ␤4 promotes faster repair in various chronic human wounds, including pressure ulcers, stasis ulcers, and epidermolysis bullosa lesions. The faster healing time with increased keratinocyte migration and angiogenesis and reduction in both inflammation and scarring are especially important for epidermolysis bullosa patients who suffer from slow healing and inflammation that leads to itching, infections, pain, fluid loss, scarring, and tissue damage. These multiple mechanisms of action support thymosin ␤4's role in accelerating dermal repair and suggest the potential to treat various types of severe wounds, including epidermolysis bullosa patients who suffer from frequent blistering wounds that can be life threatening. There is an urgent need at this time to develop a therapeutic, such as thymosin ␤4, for epidermolysis bullosa. Despite progress in gene/stem cell therapy, there is no cure for this disease and careful wound management is the standard of care.
D ermal wound healing is a multistep process that is impaired or delayed for many individuals, such as aged, immobilized, and/or diabetic patients. Furthermore, many patients suffer from deep and/or large wounds that do not heal quickly and result in significant scarring and thus loss of tissue function [1, 2] . Patients with epidermolysis bullosa suffer from repeated dermal blisters that result in painful wounds that in some forms of the disease are life-threatening [3, 4] . At this time, there is little that can be done to treat such wounds beyond meticulous wound care to prevent infection, reduce discomfort, and promote natural healing [5, 6] . A naturally-occurring molecule, thymosin ␤4, has shown promise in many preclinical animal models for repairing injured tissues, including dermal lesions and burns, ocular injury, myocardial infarct, stroke, fibrosis of the kidney and lung, traumatic brain injury, and spinal cord damage [7, 8] . Several Phase 2 clinical studies have also shown accelerated healing and tissue repair with thymosin ␤4 [9] . Many biological activities/mechanisms of action important in dermal repair have been shown for this molecule. The recent clinical successes with severe and moderate ocular injury further support the use and safety of thymosin ␤4 in severe dermal injuries [10, 11] (NCT01387347, NCT01393132, NCT02994907, NCT02597803). This review will discuss the data that support the rationale for its use in the clinic to treat problematic wounds, especially in epidermolysis bullosa patients.
Epidermolysis bullosa (EB)
EB is a rare genetic disease affecting 1 in 50,000 worldwide. The United States Epidermolysis Bullosa Registry found that the overall incidence and prevalence of inherited EB were 19.57 and 11.07, respectively [12] . It is a blistering disease in which the skin does not adhere well to the underlying tissue, resulting in lesions induced by mild trauma. EB involves defects in 20 different genes [13] . There are four main EB types: simplex (EBS: mutations in the KRT5 and KRT14 genes), dystrophic (DEB: defect in collagen VII), junctional (JEB: defect in laminin-332), and Kindler syndrome (mixed pattern of gene defects) [3] . Laminin-332 and collagen VII are basement membrane components that promote tissue integrity and keratinocyte migration. Mutations in the genes comprising these proteins (three distinct laminin chains and two distinct collagen chains) underlie some of the more severe forms of this disease [14] [15] [16] . These EB patients suffer from pain, fluid loss, anaemia, malnutrition, infections, and scarring. One complicating issue is itching which is severe and can lead to additional injury in the skin [4, 5, 13] . There is no specific treatment or cure for EB at this time beyond meticulous wound care requiring rebandaging every one to three days that can take up to two hours per day. Such care is painful for the patients and difficult for the caregivers [5] . Patients with DEB develop significant scarring leading to loss of tissue function, such as use of the hands [17] . RDEB patients more often develop squamous cell carcinoma and a recent report indicated that actually all EB patients could develop squamous cell carcinoma [17] . The quality of life is greatly diminished and life expectancy is reduced for many of these EB patients.
Clinical studies on EB
There is an urgent need to find an effective treatment for EB patients. A variety of current clinical studies are focusing on gene and/or cell therapy as well as on either topical or systemic drug treatments [18] [19] [20] [21] [22] [23] (clinicaltrials.gov) (table 1) . Such studies are progressing and offer hope for the patients. While gene therapy using either viral vectors or genetically modified autologous cells has the potential to cure EB, this treatment approach is at a very early stage and may require invasive procedures [6] . Furthermore, gene therapy will have to be developed for each mutated gene and may require harvesting of the patients own cells for gene delivery. Some gene therapy approaches have used or will use intradermal injections of genetically modified autologous fibroblasts (FCX-007), intravenous infusion of genetically modified stem cells (IMP-allo-APZ2-EB), topical gene therapy (KB103), viral transfer of the collagen VII gene to keratinocyte sheets (LZRSE-Col7A1), autologous genetically modified epidermal cells as grafts, and genetically corrected epidermal autografts (ATMP). Cellbased therapy using autologous stem cells is progressing in the clinic with several sites starting trials for EB patients using either adipose stem cells or mesenchymal stromal cells [18, 20, 21] . The expected development time for gene and/or cell therapy and potential high cost suggest that these approaches may not be available soon or to all patients. Topical treatments are also being tested on EB patients. Topical gentamicin has recently shown effectiveness in increasing collagen VII synthesis and healing wounds in DEB patients with nonsense mutations in collagen VII [16, 24] . A Phase 1/2 trial (NCT03526159) using systemic and topical gentamicin treatment is recruiting. A topical treatment, Oleogel S-10, consisting of a plant extract that reduces inflammation and promotes keratinocyte migration, has advanced to Phase 3 trials [25] . A topical anti-inflammatory, Diacerein, has completed a small 15patient Phase 2 trial with efficacy for EB simplex [26] , and is recruiting by invitation for its long-term safety trial (NCT03389308). Another topical treatment, Zorblisa, unfortunately failed to show significant efficacy in a recent Phase 3 trial (clinicaltrials.gov, NCT02384460), and oral polyphenon E failed to show efficacy in a Phase 2 trial [27] . Based on preclinical studies, a topical antisense nucleotide (QR313) is being tested (NCT03605069) for patients with an exon 73 mutation in Col7 [28] . Because of the immediate need to treat EB patients, effective topical treatments for now have the potential to promote healing, relieve the symptoms, and improve the quality of life of EB patients [6] . Thymosin ␤4 is one topical treatment that is multifunctional, and preclinical and clinical studies have provided the scientific rationale for its use with all EB patients [7, 29] . Thymosin ␤4, as detailed below, has multiple mechanisms of action that not only reduce inflammation but also protect the tissue and drive the endogenous healing process, resulting in fast wound healing. In an ad hoc analysis, thymosin ␤4 also showed a trend toward efficacy in JEB and DEB patients in a small 30-patient multi-dose Phase 2 trial (NCT00311766) (figure 1).
Thymosin ␤4 regenerative activities
Thymosin ␤4 distribution and functions
Originally described for its effects on the immune system, thymosin ␤4 has, in the last 20+ years, showed consistent strong effects on promoting tissue repair and regeneration in many diverse organs and in various preclinical models of tissue injury [7] [8] [9] [30] [31] [32] [33] [34] [35] . It is a small 4.9 kDa molecule that is present in almost all cells and body fluids, including wound fluid [36] [37] [38] [39] [40] . It has multiple activities (table 2) that explain its ability to improve healing in so many organs with different causes of injury. It reduces inflammation by preventing NFkappa B activation, resulting in a reduction in the secretion of various inflammatory mediators [41] [42] [43] [44] . Scarring is reduced, in part, by blocking the presence of fibroblasts and by allowing for normal collagen synthesis with faster and appropriate organization of the collagen fibrils [45] (table 3) . A reduction in scar tissue has been observed by multiple research groups in different animal models of injury, including excisional wounds, myocardial infarct, stroke, and fibrosis of the lung, liver, and kidney [44] [45] [46] [47] [48] [49] [50] [51] (table 2) . Thymosin ␤4 reduces oxidative stress by targeting anti-oxidative genes [52] [53] [54] [55] [56] [57] . It reduced toxicity by inhibiting inducible nitric oxide synthetase (iNOS) and cyclooxygenase-2, resulting in decreased reactive oxygen species (ROS), decreased secretion of NO, and decreased prostaglandins. Thymosin ␤4 decreased apoptosis by increasing anti-apoptotic proteins, such as caspases and decreasing the Bax/BCL2 ratio [58] [59] [60] . This results in cell/tissue survival. Angiogenesis is important for healing wounds as the vasculature provides a way to remove the debris and to supply nutrients for the forming tissue [61] . Thymosin ␤4 promotes VEGF synthesis and endothelial progenitor cell migration/recruitment and differentiation, leading to new blood vessel formation [61] [62] [63] [64] [65] [66] [67] [68] . Thymosin ␤4 also prevents microbial infection [69] . This activity was unexpectedly discovered when researchers were identifying antimicrobial peptides in activated platelets. Platelets are known to be important in host defense and thymosin ␤4 was found to be one of seven antimicrobial peptides in platelets. The mechanism of action of thymosin ␤4 on microbes is not known. An especially important activity is the ability to promote cell migration in various injury models, and particularly the migration of keratinocytes which cover the wound and protect from fluid loss and infection [7, 46, 60, 65, 70, 71] . The migration activity of thymosin ␤4 is, in part, mediated by its binding to actin. Thymosin ␤4 binds to actin, and the actin binding domain has been identified as the site responsible for cell migration [57] . Thymosin ␤4 coordinates actin polymerization with metalloproteinase synthesis to promote cell migration. One mechanism proposes that profilin-dependent dissociation of the G-actin-thymosin ␤4 complex liberates actin for filament assembly [71] . Thymosin ␤4 binds to integrinlinked kinase in the lamellipodia to both activate Akt2 and increase metalloproteinase production [72] . In addition, Figure 1 . Thymosin ␤4 decreases the EB wound area (% change) after 14 days of topical treatment more effectively than the placebo, especially for the larger wounds. Patients were treated topically daily, and the wound area was measured at Day 15.
These results show the faster healing by thymosin ␤4 and its ability to be effective for large wounds. Note that all doses of thymosin ␤4 were more effective than the vehicle control for all wound sizes. Data were obtained based on an ad hoc analysis of NCT-311766.
thymosin ␤4 increases laminin-332 synthesis which is a known migration factor for various epithelial and endothelial cells, including keratinocytes [70, 73, 74] . Laminin-332 also promotes tissue integrity by increasing keratinocyte adhesion to the underlying extracellular matrix [14, 75] . It should be noted that the underlying defect in JEB involves mutations in laminin-332. This mutation results in the loss of the function of this molecule and the blistering of the skin in JEB [13] [14] [15] [16] . Taken together, thymosin ␤4 has the potential to heal and regenerate dermal injuries of various causes. The multiple mechanisms of action of thymosin ␤4 are important in all of the major stages of dermal wound healing, including inflammation, proliferation, and remodelling. Such a large range of activities provide the scientific rationale for its potential to heal epidermolysis bullosa wounds caused by different genetic defects.
Thymosin ␤4 active sites
How can one molecule have so many biological activities? Several active sites within the molecule have been identified [43, 44, 47, 49, 62, [76] [77] [78] . The amino terminal SDKP sequence (amino acids 1-4) is naturally found in plasma and is responsible for the anti-inflammatory and anti-fibrotic effects [43, 44, 47, 49, 79] . Thymosin ␤4 is the only protein known to contain the SDKP sequence. It is interesting to note that decreased serum levels of SDKP result in organ fibrosis, thus demonstrating its protective effect [79] . The amino terminal 15 amino acids (amino acids 1-15) contain the tissue protective and anti-apoptotic activity [78] . The central LKKTETQ sequence (amino acids 17-23) binds to actin and is found naturally in wound fluid [39] . LKK-TETQ promotes cell migration, angiogenesis, hair growth, and dermal repair [7] .
Thymosin ␤4 preclinical dermal repair studies
Almost 30 years ago, the first animal study showing the effectiveness of topical thymosin ␤4 on rat dermal wounds Figure 2 . Thymosin ␤4 increases wound closure and collagen deposition after seven days, in rat skin full-thickness punch wounds: A) vehicle; B) thymosin beta 4. Sections were stained with Masson's trichrome to visualize collagen I (blue). Animals received six 6-mm full-thickness punch wounds and were treated with either placebo or thymosin ␤4 on Days 0 and 2. Note in the treated tissue, the increase in granulation tissue (Y) containing collagen I (darker blue staining) in the centre of the wound, the increase in hair follicles (Z) at the wound edge, and increase in keratinocyte migration (white arrows indicate leading edge of the migrating keratinocytes) to cover the wound gap. The figure is taken from [28] , representing work done by HKK while a US government employee. V: crust; W: epidermis; X: dermis; black arrows indicate blood vessels.
reported an acceleration of healing (table 4) . When compared to placebo-treated wounds, the treated rat dermal wounds healed more quickly with increased keratinocyte migration across the wound surface, faster deposition of granulation tissue, increased collagen deposition and maturation, and increased angiogenesis [30] ( figure 2) . Additional studies in mice, aged mice, diabetic mice, mice with dermal burns, and steroid-treated rats confirmed the efficacy of thymosin ␤4 in accelerating dermal wound closure [7, 9, 45, 58, 66, 76, 80, 81] . It is important to note that thymosin ␤4 showed good efficacy with both normal and impaired healing models. The survival of skin flaps was also improved by thymosin ␤4 [82] . Most studies used topical thymosin ␤4 that was synthetically prepared and commercially available. Recombinant thymosin ␤4 was equally effective as the synthetic form [83] and a dimeric form was found to be more active [84] . In some studies, thymosin ␤4 was injected either intraperitoneally or intradermally and showed good efficacy. One unexpected finding was that thymosin ␤4 accelerated hair growth in several models, including aged mice, diabetic mice, nude mice, rats ( figure 2) , and mice treated with chemotherapeutic agents [7, [85] [86] [87] . Furthermore, genetically modified cashmereproducing goats and mice that were both overexpressing thymosin ␤4 in their skin show increased hair production [88, 89] . For hair growth, thymosin ␤4 activated the resting follicles by increasing progenitor cell migration from the bulge region to the root and promoted differentiation [90] . In summary, thymosin ␤4 is active in accelerating dermal repair in various preclinical models of both normal and impaired healing. The healing effects do not appear to depend on the mode of administration.
Thymosin ␤4 clinical studies Dermal studies Thymosin ␤4 was shown to be safe and well tolerated in all of the clinical trials to date. Phase 1 trials for safety of topically as well as intravenously delivered thymosin ␤4 have been performed. Its safety was initially confirmed when used in high doses, either topically or systemically, for all of the 15 healthy control patients in the Phase 1 dermal topical safety studies and for all of the 40 patients in the Phase 1 systemic studies [7, 9, 91] . In Phase 2 trials, three doses were tested topically and daily for pressure ulcers (Stages 3 and 4) in 71 patients (NCT00382174) and for venous stasis ulcers in 72 patients (NCT00832091). The studies reported that the mid dose (0.02/0.03%) of thymosin ␤4 in both trials accelerated healing over that seen with the placebo groups. The median time to complete healing of the pressure wounds that healed in the treated vs placebo pressure ulcer groups was 22 vs 57 days (not significant due to the small sample size of 17-19 patients per arm).
The median time to complete healing of the stasis ulcers that healed in the treated vs placebo stasis ulcer groups was 39 vs 71 days (again, not statistically significant due to small sample size of 17-19 patients per arm). A small study (NCT00311766) was performed with 30 epidermolysis bullosa patients (JEB and DEB) investigating three topical doses (0.01, 0.03, and 0.10 %) of thymosin ␤4 [7] . At Day 14, ad hoc analysis found that all three doses showed a trend to better efficacy than that in the placebo group ( figure 1) . The primary endpoint of complete healing at 56 days was not met. This is a difficult endpoint for JEB and DEB patients. Recognizing this problem, the FDA has recently revised the guidelines for EB patients and 100% healing is no longer required [92] . The data were analysed based on wound size at baseline at Day 15. All three doses trended toward better efficacy than the placebo for all wound sizes at baseline. The large wounds healed very poorly in the placebo group (not statistically significant due to small sample size). The treated large wounds healed faster than those of the placebo group with similar efficacy to that in all of the wound size groups. These data, in combination with the other dermal trials, suggest the faster healing potential for treating EB patients with thymosin ␤4. Furthermore, there were no safety or tolerability issues in these fragile patient populations (elderly, diabetic, or JEB/DEB) from which a combined total of 129 patients received thymosin ␤4.
Rationale for potential of thymosin ␤4 to treat EB patients
The faster healing observed in the preclinical animal models and in the Phase 2 dermal studies would greatly benefit EB patients [7, 9] . It should be noted that many of the animal models represent impaired healing, such as aged, diabetic, and steroid-treated animals. All three clinical trials with pressure ulcers, stasis ulcers, and EB patients also represent fragile and compromised patient populations. Such studies indicate the safety of thymosin ␤4 for EB patients. Furthermore, EB patients would likely have faster healing with thymosin ␤4. The faster healing in the dermal studies further reinforces the efficacy of thymosin ␤4 and its appropriateness for treating EB patients. Reduction in the wound size by even 50% would greatly benefit the EB patient by reducing the pain, fluid loss, itching, and opportunity for infection. The mechanisms of action, including anti-inflammation, keratinocyte migration, adherence of the keratinocytes to the wound bed, and upregulation of extracellular matrix proteins (laminin-332), are also important to the EB dermal repair process [7] (table 2) . The reduction in inflammation would reduce the pain, itching, and scarring. Laminin-332 is upregulated by thymosin ␤4 and is involved in keratinocyte migration and adhesion and the structural integrity of the epidermal-dermal junction [7, 8, 16] . In JEB, laminin-332 is mutated, indicating the importance of this gene to dermal tissue maintenance.
Summary and future applications
Why do we need a topical agent like thymosin ␤4 when gene therapy has the potential to cure EB and other severe wounds and is progressing so well toward the clinic? Unfortunately, it is not clear when gene therapy for these indications will be available and if it will be available for all patients and for all forms of the disease given that 20 genes have been described with defects [6, 13] . Patients need immediate effective treatment because the standard of care involving bandaging and symptom relief is not effective in preventing the pain, loss of tissue function, and early death of many EB patients. The multifunctional regenerative protein, thymosin ␤4, has shown significant efficacy for healing in different impaired healing animal models with different underlying causes [7, 8] . Thymosin ␤4 has the potential to be used systemically as well since in preclinical models involving injury to the skin, heart, and brain, it showed good efficacy when given systemically [35, 46, 48, 50, 57, 60, 64, 93] . Furthermore, the efficacy was observed with a single treatment in the skin and heart and with treatments every third day for the brain. In addition, a Phase 1 systemic study showed an excellent safety profile. Safety was further observed with a genetically modified mouse with thymosin ␤4 overexpression in the skin [89] . This mouse survived and produced offspring with the only observable differences being an increased amount of hair and discoloured teeth. Finally, naturally increased endogenous serum levels have been associated with better survival in scleroderma, septic shock, and liver fibrosis patients [94] [95] [96] . Higher serum levels are also associated with corollary capillary development in heart patients [63] . Thus, in the future, systemic thymosin ␤4 has the potential to be an effective and safe treatment for all EB patients and for other serious dermal injuries. If systemic therapy is considered, the dosage must be carefully adjusted as thymosin ␤4 is a biological molecule with at least one known receptor, ATP synthase, that acts by purinergic signalling [97] . Systemic dose response studies in animal models have found that the higher doses may be less effective [50] . A similar 'bell shaped' curve of activity was also seen in the venous stasis and pressure ulcer Phase 2 trials [9] . Finally, other severe dermal injuries might benefit from thymosin ␤4. Preclinical studies have reported efficacy in healing dermal burns and promoting skin flap attachment/survival, the latter of which may be important for mastectomy patients and for skin grafts [81, 82] . Surgical wounds and trauma may also benefit from treatment with thymosin ␤4. Systemic thymosin ␤4 would be expected to repair and regenerate tissue in patients with internal injuries. For example, elevated systemic thymosin ␤4 reduces liver fibrosis and bleomycin-induced lung damage [98, 99] . In addition, when implanted in a slow-release complex, it also prevents tissue loss after myocardial infarction [100] . A viral vector overexpressing thymosin ␤4 has shown efficacy in a pig model of reperfusion injury in the heart [101] , and this gene therapy approach may be used in the future for EB patients and for patients with other severe dermal injuries. One advantage is that viral delivery of thymosin ␤4 would have the potential to benefit all genetic forms of EB.
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